B+
Bull case
25%
Probability
Target price
$2.60
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
ADIL
AdialFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The post-earnings company update modestly improved the operating narrative by linking AD04 to a potentially more flexible FDA evidentiary framework, lower possible Phase 3 burden, European partnership discussions, and longer-dated IP protection if granted [#8-K-2026-05-11].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
AD04's Phase 3 path is still dependent on ongoing regulatory discussions and final trial design, so the hoped-for reduction in trial burden is not yet secured [#8-K-2026-05-11] [#10-Q-2026-05-08].
Momentum
71
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.00 · Bull $2.60 · Bear $0.35Analysis 2026-05-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $8.50
Why
Momentum71 · Δ7d -
Value41 · Δ7d -0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • AD04's Phase 3 path is still dependent on ongoing regulatory discussions and final trial design, so the hoped-for reduction in trial burden is not yet secured [#8-K-2026-05-11] [#10-Q-2026-05-08].
- • Further equity issuance is likely if the company continues funding AD04 internally, creating meaningful dilution risk through ATM, equity line, or other capital raises [#10-Q-2026-05-08].
- • The same earnings follow-up still reads as a monitoring story because the company remains funding constrained, the 10-Q keeps substantial-doubt language, and advancement of AD04 still depends on additional capital and unresolved regulatory execution [#10-Q-2026-05-08].
Catalyst clock
2026-09-30
Q1 update preserved only a short runway and keeps financing risk front and center
Lead driver: Value · See fundamentals
Momentum
71
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 71.2 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.00
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$13.1M
Beta
1.26
Shares Out
2.19M
P/E (TTM) · Derived
-0.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.03
Rev YoY
-
EPS YoY
+144.1%
Gross Margin
-
Op Margin
-
Net Debt
-$5.88M
Current Ratio
5.63
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data